These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23218868)

  • 21. Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.
    Murry L; Gerleman B; Urick B; Urmie J
    J Am Pharm Assoc (2003); 2018; 58(4):421-425. PubMed ID: 29861152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prescription-drug coupons--no such thing as a free lunch.
    Ross JS; Kesselheim AS
    N Engl J Med; 2013 Sep; 369(13):1188-9. PubMed ID: 23984672
    [No Abstract]   [Full Text] [Related]  

  • 23. Knowledge, Experience, and Perceptions of Generic Drugs among Middle-Aged Adults and their Willingness-to-Pay: A Nationwide Online Survey in Japan.
    Ito Y; Hara K; Sato H; Tomio J
    Tohoku J Exp Med; 2021 Sep; 255(1):9-17. PubMed ID: 34497247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs.
    Ito Y; Hara K; Yoo BK; Tomio J; Kobayashi Y
    BMC Health Serv Res; 2019 Nov; 19(1):780. PubMed ID: 31675967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Health insurance discount contracts: problems and risks for the general practitioner in the medical care of patients with chronic illness].
    Leutgeb R; Mahler C; Laux G; Weschnetz A; Szecsenyi J
    Dtsch Med Wochenschr; 2009 Jan; 134(5):181-6. PubMed ID: 19180404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Americans' access to prescription drugs stabilizes, 2007-2010.
    Boukus ER; Carrier ER
    Track Rep; 2011 Dec; (27):1-5. PubMed ID: 22180943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Spending on Common Generic Drugs by Medicare vs Costco Members.
    Trish E; Gascue L; Ribero R; Van Nuys K; Joyce G
    JAMA Intern Med; 2021 Oct; 181(10):1414-1416. PubMed ID: 34228050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of Copayment Offsets for Prescription Drugs in the United States.
    Sen AP; Kang SY; Rashidi E; Ganguli D; Anderson G; Alexander GC
    JAMA Intern Med; 2021 Jun; 181(6):758-764. PubMed ID: 33779680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing.
    Bazalo G; Weiss RC
    Consult Pharm; 2012 Apr; 27(4):269-73. PubMed ID: 22498986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Undocumented source of pharmacy benefit manager revenue.
    Siracuse MV; Clark BE; Garis RI
    Am J Health Syst Pharm; 2008 Mar; 65(6):552-7. PubMed ID: 18319501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
    Morgan SG; Li W; Yau B; Persaud N
    CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consumer perceptions of risk and required cost savings for generic prescription drugs.
    Ganther JM; Kreling DH
    J Am Pharm Assoc (Wash); 2000; 40(3):378-83. PubMed ID: 10853539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.
    Fischer MA; Avorn J
    Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):207-14. PubMed ID: 15255087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Favorable Formulary Placement of Branded Drugs in Medicare Prescription Drug Plans When Generics Are Available.
    Socal MP; Bai G; Anderson GF
    JAMA Intern Med; 2019 Jun; 179(6):832-833. PubMed ID: 30882842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Medicare Part D on independent and chain community pharmacies in rural Illinois--A qualitative study.
    Bono JD; Crawford SY
    Res Social Adm Pharm; 2010 Jun; 6(2):110-20. PubMed ID: 20511110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generic medications for you, but brand-name medications for me.
    Keenum AJ; Devoe JE; Chisolm DJ; Wallace LS
    Res Social Adm Pharm; 2012; 8(6):574-8. PubMed ID: 22357268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
    Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
    Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
    Hoadley JF; Merrell K; Hargrave E; Summer L
    Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.